Loading...
Market
What will be the outcome of Editas Medicine's $238 million biobucks agreement by end of 2025?
3
Resolution / Starting Odds
Full agreement executed • 25%
Partial execution • 25%
Agreement terminated • 25%
No significant progress • 25%
Official announcements from Editas Medicine or financial reports
Story
Editas Medicine Shifts Focus to In Vivo Gene Therapy for Sickle Cell, Signs $238 Million Biobucks Pact
Oct 24, 2024, 05:36 AM
Editas Medicine is shifting its focus from its lead ex vivo sickle cell treatment to an in vivo gene therapy approach. The company has signed a $238 million biobucks agreement and is seeking a partner for its advanced ex vivo sickle cell disease program. Editas aims to achieve proof-of-concept data and become the first CRISPR-focused company to declare in vivo sickle cell treatment as its lead program. This strategic pivot, announced on Tuesday, is seen as a significant breakthrough in the field of CRISPR gene editing, although major hurdles remain.
View original story
Similar markets
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Data Released • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Novartis • 25%
Roche • 25%
Other • 25%
Company A exceeds $10 billion • 25%
Company B exceeds $10 billion • 25%
Both companies exceed $10 billion • 25%
Neither company exceeds $10 billion • 25%
Xaira Therapeutics • 25%
Mirador Therapeutics • 25%
Formation Bio • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
